NeurologyLive® Friday 5 — December 24, 2021

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: An Emerging Framework for Parkinson Disease Therapeutics

As part of NeurologyLive^®'s December 2021 issue, our guest editor-in-chief Jeffrey Ratliff, MD, offers insight into the diagnosis of Parkinson disease, which may seem straightforward at first by requiring neurologists to rely on their eyes and hands. But the treatment process can present challenges for both physicians and patients.

2: How Insomnia Affects Both Day and Night

Michael J. Thorpy, MD, ChB, Karl Doghramji, MD, Erinn E. Beagin, MD, Nathaniel Fletcher Watson, MD, Vikas Jain, MD, FAASM, FAAFP, CCSH, CPE, offer shared insight on how daytime functioning has become part of the insomnia treatment paradigm in episode 2 of the NeurologyLive® Peer Exchange™ series, "Unmet Needs in Treating Insomnia."

3: A Practical Approach to Chronic Immunosuppression in Myasthenia Gravis

Ericka Wong, MD, and Jessica Yi, MD, offer a practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.

4: NeuroVoices: Dejan Jakimovski, MD, PhD, on Identifying A Relationship Between Brain Structures and Cognitive Performance in MS

The research assistant professor in the department of neurology at the Buffalo Neuroimaging Analysis Center spoke to a grant from the Consortium of Multiple Sclerosis Centers (CMSC) to study the relationship between brain structure and cognitive performance in elderly people with multiple sclerosis.

5: The Implications of Aducanumab’s Price Reduction for Alzheimer Disease

George Vradenburg, JD, the chair and cofounder of UsAgainstAlzheimer’s; and Ian N. Kremer, JD, executive director, Leaders Engaged on Alzheimer's Disease, offer their insight into the downstream effects of the new pricing of Biogen’s aducanumab (Aduhelm).

—————————————————

Introducing: Giants of Multiple Sclerosis™

Recognize and celebrate the individuals who have achieved landmark successes within multiple sclerosis! Giants of Multiple Sclerosis™ is a premier neuroscience award that celebrates pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in Multiple Sclerosis.

Nominate Someone Today for a 2022 Giants of Multiple Sclerosis™ Award

• Nominations are open through January 31, 2022
• The Giants of Multiple Sclerosis™ Steering Committee will vet all nominations and vote to determine the 2022 inductees
• Nominees will be selected on the merits of their lifetime work.
• One honoree in each category who makes a measurable difference in the lives of patients will be awarded.
• The 2022 Giants of Multiple Sclerosis™ inaugural class will be announced in Spring of 2022

Nominate someone here.